Ravinder Bachireddy, MD
Interventional Cardiology · Lufkin, TXNPI 1023094703
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Eli Lilly at 32.0% of the total. Reporting peaked in 2024 at $3,866 and has fallen 66.6% since, to $1,291 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 166 payments — averaging $43.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Boston Scientific$2K
- Medtronic$1K
- Novartis$228
- Abiomed$184
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$181
- plus $925 from 11 others
Across 6 payments — averaging $35,033 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$210K
What the payments were for
- Travel & lodging$3,06143%
- Food & beverage$4,09957%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 15 | $2,297 |
| Boston Scientific | 39 | $2,015 |
| Medtronic(2 entities) | 27 | $1,344 |
| Novartis | 39 | $228 |
| Abiomed | 4 | $184 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $181 |
| Inari Medical, Inc. | 5 | $175 |
| Abbott | 5 | $161 |
| E.r. Squibb & Sons, L.L.C. | 7 | $153 |
| Angiodynamics, Inc. | 1 | $123 |
| Johnson & Johnson | 3 | $68 |
| Merck | 3 | $56 |
| Cook Medical LLC | 1 | $52 |
| AstraZeneca | 3 | $46 |
| Bard Peripheral Vascular, Inc. | 2 | $45 |
| Cardinal Health 200 LLC | 1 | $32 |
| Bsn Medical Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Varithena Administration Pack$1,080
- Abre$238
- EKOSONIC$143
- ClosureFast$140
- VenaSeal$120
- Impella$112
- Micra$103
How this compares
$7,175 in reported general payments places this provider in the 40th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 664 | $590,201 |
| XareltoRivaroxaban | 299 | $230,133 |
| EntrestoSacubitril/Valsartan | 56 | $62,375 |
| BrilintaTicagrelor | 47 | $32,319 |
| Metoprolol Succinate | 1,173 | $23,574 |
| Amiodarone Hcl | 287 | $8,192 |
| Losartan Potassium | 389 | $4,963 |
| ClopidogrelClopidogrel Bisulfate | 363 | $4,840 |
| Amlodipine Besylate | 528 | $4,560 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 355 | $4,130 |
| Potassium Chloride | 195 | $3,772 |
| Metoprolol Tartrate | 334 | $2,891 |
| Carvedilol | 300 | $2,808 |
| Lisinopril | 310 | $2,210 |
| Atorvastatin Calcium | 266 | $2,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $68 | $230,133299 claims |
| NovartisEntresto | $228 | $62,37556 claims |
| AstraZenecaBrilinta | $46 | $32,31947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Lufkin
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.